PDCD1LG2 and neoplasm: PD-1 inhibitors directly block the binding of PD-1 to its ligands PD-L1 and PD-L2, which completely deregulates the immunosuppressive signaling, strongly activates T cells, and enhances the anti-tumor immune response.